Immunotherapy: HLA genotype: good to be different – Nature.com
Nature.com |
Immunotherapy: HLA genotype: good to be different
Nature.com Immune checkpoint blockade (CPB) — targeting checkpoint inhibitors such as programmed cell death protein 1 (PD1) to enhance the antitumour activity of CD8+ T cells — has revolutionized the treatment of some advanced-stage cancers, such as melanoma … |
